Haemonetics (NYSE:HAE) Issues Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Haemonetics (NYSE:HAE) posted its quarterly earnings data on Thursday. The medical instruments supplier reported $1.14 EPS for the quarter, beating the consensus estimate of $1.08 by $0.06, FiscalAI reports. The firm had revenue of $339.38 million during the quarter, compared to the consensus estimate of $327.86 million. Haemonetics had a return on equity of 27.55% and a net margin of 7.12%.The firm’s revenue was up 5.5% compared to the same quarter last year. During the same period in the prior year, the company earned $1.10 EPS.

Here are the key takeaways from Haemonetics’ conference call:

• Haemonetics raised fiscal 2027 guidance, now expecting reported revenue growth of 5%–8% and organic growth of 4%–7%, following first-quarter revenue growth of 6% and adjusted EPS growth of 4% to $1.14.
• Plasma revenue increased 8% organically, supported by double-digit disposable growth, share gains, strong collection volumes, and the early rollout of Persona PLUS, which is delivering more than 5% yield improvements for early adopters.
• Interventional technologies returned to growth, led by low-double-digit vascular closure growth. The VASCADE MVP XL indication expansion, new clinical evidence, and stronger sales execution are supporting account wins and increased utilization in PFA and other large-bore procedures.
• Cash generation was strong, with operating cash flow tripling year over year to $52 million and trailing-12-month free-cash-flow conversion reaching 106% of adjusted net income. The company used cash to repay $100 million of revolver debt and retains flexibility for growth investments and opportunistic share repurchases.
• External cost pressures remain a headwind, including tariffs, transportation and oil-related costs, material inflation, and higher personnel expenses. Slower cell-salvage capital upgrades and weakness in OEM and esophageal-cooling businesses also weighed on parts of MedSurg and interventional technologies.

Haemonetics Trading Up 2.9%

Shares of HAE stock traded up $2.48 during trading hours on Friday, hitting $87.50. The company had a trading volume of 657,064 shares, compared to its average volume of 737,142. The company has a debt-to-equity ratio of 1.40, a current ratio of 3.08 and a quick ratio of 1.87. The stock has a market capitalization of $3.98 billion, a PE ratio of 42.89, a price-to-earnings-growth ratio of 1.71 and a beta of 0.52. The company’s fifty day moving average is $76.98 and its 200 day moving average is $66.52. Haemonetics has a fifty-two week low of $47.31 and a fifty-two week high of $88.58.

Haemonetics News Summary

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Haemonetics reported fiscal Q1 2027 earnings of $1.14 per share, exceeding the $1.07–$1.08 consensus range. Revenue rose 5.5% year over year to $339.4 million, also comfortably ahead of expectations near $327.9 million. The earnings and sales beats indicate continued operating momentum. Haemonetics Tops Q1 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its fiscal 2027 outlook and now expects reported revenue growth of approximately 5% to 8%. The improved forecast, following a strong first quarter, supports the view that demand and execution are better than previously anticipated. Haemonetics Raises Fiscal 2027 Revenue Guidance
• Positive Sentiment: BTIG Research raised its Haemonetics price target from $84 to $96 and maintained a “buy” rating, implying additional upside based on the company’s earnings performance and outlook. BTIG Raises Haemonetics Price Target
• Neutral Sentiment: Citigroup lifted its price target from $79 to $92, while retaining a “neutral” rating. The higher target reflects improved estimates but suggests limited conviction at the current valuation. Citigroup Analyst Update
• Neutral Sentiment: JPMorgan raised its target from $62 to $86 but maintained a “neutral” rating. The revised target remains slightly below the recent trading level, signaling that valuation may constrain further gains despite the improved outlook. JPMorgan Analyst Update

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Raymond James Financial reiterated an “outperform” rating and issued a $105.00 target price on shares of Haemonetics in a research report on Friday. Robert W. Baird set a $96.00 price target on shares of Haemonetics in a research report on Friday. Citigroup upped their price objective on shares of Haemonetics from $79.00 to $92.00 and gave the company a “neutral” rating in a research note on Friday. Weiss Ratings upgraded shares of Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, June 25th. Finally, Wall Street Zen upgraded Haemonetics from a “buy” rating to a “strong-buy” rating in a report on Saturday. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, Haemonetics presently has an average rating of “Moderate Buy” and a consensus target price of $90.89.

Institutional Trading of Haemonetics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Kemnay Advisory Services Inc. acquired a new position in Haemonetics during the fourth quarter worth $26,000. EverSource Wealth Advisors LLC grew its stake in shares of Haemonetics by 2,640.0% in the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after buying an additional 396 shares in the last quarter. Kestra Advisory Services LLC acquired a new stake in shares of Haemonetics in the fourth quarter valued at $34,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of Haemonetics by 20,925.0% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 841 shares of the medical instruments supplier’s stock valued at $41,000 after buying an additional 837 shares during the period. Finally, UMB Bank n.a. raised its holdings in shares of Haemonetics by 110.9% in the 4th quarter. UMB Bank n.a. now owns 582 shares of the medical instruments supplier’s stock valued at $47,000 after buying an additional 306 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.